Table 1.

Identified ALK fusion proteins and their associated malignancies. Known ALK fusion proteins and the cancers they have been identified in are indicated. ALCL: anaplastic large cell lymphoma; DLBCL: diffuse large B-cell lymphoma; IMT: inflammatory myofibroblastic tumour; NSCLC: nonsmall cell lung carcinoma; RCC: renal cell carcinoma; SCC: squamous cell carcinoma.

Fusion protein	Tumour type	Reference
NPM-ALK	ALCL, DLBCL	[20–22]
TPM3-ALK	ALCL, IMT, RCC	[23–26]
TFG-ALK	ALCL, NSCLC	[27, 28]
ATIC-ALK	ALCL, IMT	[29–32]
CLTC-ALK	ALCL, DLBCL, IMT, extramedullary plasmacytoma	[33–38]
TPM4-ALK	IMT, ALCL, SCC	[25, 39–41]
MSN-ALK	ALCL	[42]
ALO17-ALK	ALCL	[43]
CARS-ALK	IMT	[43]
RANBP2-ALK	IMT	[44]
MYH9-ALK	ALCL	[45]
SEC31L1-ALK	IMT, DLBCL	[46–48]
EML4-ALK	NSCLC, breast, colorectal, RCC	[26, 28, 49, 50]
SQSTM1-ALK	DLBCL	[51]
VCL-ALK	RCC	[52, 53]
KIF5B-ALK	NSCLC	[54]
PPFIBP1-ALK	IMT	[55]
C2orf44-ALK	Colorectal	[56]
KLC1-ALK	NSCLC	[57]